Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Tsuduki, H. Tateno, H. Nakamura, S. Tsujimura, M. Nakamura, T. Shirahata, K. Asano (Shinjuku, Saitama, Japan). Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model. Eur Respir J 2010; 36: Suppl. 54, 1376

Member's Comments

No comment yet.

Related content which might interest you: Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma Source: Eur Respir J 2016; 47:1568-1571 Year: 2016 Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 suppresses allergic asthma in a murine model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 Regulation of plasminogen activator activity by inflammatory mediators in lung epithelial cells Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007 The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients Source: Annual Congress 2004 - Skeletal muscle in respiratory disease Year: 2004 Soluble urokinase-type plasminogen activator receptor in monitoring of treatment response in acute exacerbation of chronic obstructive pulmonary disease Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017 The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Lung fibroblasts regulate the urokinase-type plasminogen activator receptor (uPAR) expression of alveolar epithelial cells and endothelial cells Source: Eur Respir J 2006; 28: Suppl. 50, 397s Year: 2006 Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 Urokinase plasminogen activator receptor variants drive distinct phenotypes in the bronchial epithelium Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015 The effect of prostaglandin (PG) E2 and its receptor antagonists on urokinase-type plasminogen activator (uPA) production by human lung fibroblasts Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Influence of prostaglandin E2 on cell surface urokinase-type plasminogen activator expression and activity in lung adenocarcinoma cell line Source: Eur Respir J 2005; 26: Suppl. 49, 457s Year: 2005 Selective decoy-mediated inhibition of activator protein-1 activity in the airways prevents experimental asthmatic inflammation Source: Annual Congress 2005 - Regulation of the allergic and asthmatic response Year: 2005 SERPINE1 -675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response Source: Eur Respir J 2011; 38: 1036-1043 Year: 2011 Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Role of thrombin and thrombin receptor in the activation of human bronchial epithelial cells during airway inflammation Source: Eur Respir J 2007; 30: Suppl. 51, 523s Year: 2007 Human lung microvascular endothelial cells (HMVEC-L) angiogenic activity is inhibited by stable plasminogen activator inhibitor-1 (PAI-1) mutants via urokinase-dependent pathway Source: Annual Congress 2004 - Lung development and cancer Year: 2004 Proapoptotic and anti-proliferative effect of the stable plasminogen activator inhibitor type 1 (PAI-1) mutant on the lung cancer and endothelial cells Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009